Valsts: Izraēla
Valoda: angļu
Klimata pārmaiņas: Ministry of Health
SEMAGLUTIDE
NOVO NORDISK LTD., ISRAEL
A10BJ06
SOLUTION FOR INJECTION
SEMAGLUTIDE 1.34 MG / 1 ML
S.C
Required
NOVO NORDISK A/S, DENMARK
SEMAGLUTIDE
Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of • ≥30 kg/m2 (obesity), or • ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.
2023-04-23
1 Patient leaflet in accordance with the Pharmacists' Regulations (Preparations) - 1986 This medicine is dispensed with a doctor’s prescription only Wegovy ® 0.25 mg Wegovy ® 0.5 mg Wegovy ® 1 mg Wegovy ® 1.7 mg Wegovy ® 2.4 mg Solution for injection in pre-filled pen Active ingredient Wegovy 0.25 mg semaglutide 0.68 mg/ml Wegovy 0.5 mg semaglutide 1.34 mg/ml Wegovy 1 mg semaglutide 1.34 mg/ml Wegovy 1.7 mg semaglutide 2.27 mg/ml Wegovy 2.4 mg semaglutide 3.2 mg/ml Inactive ingredients and allergens in the medicine: See section 2 'Important information about some of this medicine’s ingredients' and section 6 'Additional information'. Read the entire leaflet carefully before you start using this medicine. This leaflet contains concise information about this medicine. If you have any further questions, consult your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if it seems to you that their medical condition is similar to yours. 1. What is this medicine intended for? Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of • ≥ 30 kg/m 2 (obesity), or • BMI ≥ 27 kg/m 2 to < 30 kg/m 2 (overweight) in the presence of at least one weight- related comorbidity, e.g. impaired blood sugar control (dysglycaemia; prediabetes or type 2 diabetes), hypertension, dyslipidaemia (impaired blood lipid control), obstructive sleep apnoea or cardiovascular disease (disease of the heart and blood vessels) BMI (Body Mass Index) is a measure of weight in relation to height. 2 Therapeutic group: Medicines for treatment of diabetes, glucagon-like peptide-1 (GLP-1) analogues. The active substance semaglutide is similar to a natural hormone called glucagon- like peptide-1 (GLP-1) that is released from the intestine after a meal. It works by acting on target proteins (receptors) in the brain that control Izlasiet visu dokumentu
1. NAME OF THE MEDICINAL PRODUCT Wegovy ® 0.25 mg Wegovy ® 0.5 mg Wegovy ® 1 mg Wegovy ® 1.7 mg Wegovy ® 2.4 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION _ _ _Wegovy 0.25 mg FlexTouch solution for injection _ Each pre-filled pen contains 1 mg semaglutide* in 1.5 mL solution. One mL of solution contains 0.68 mg semaglutide*. One pre-filled pen contains 4 doses of 0.25 mg. _Wegovy 0.5 mg FlexTouch solution for injection _ Each pre-filled pen contains 2 mg semaglutide* in 1.5 mL solution. One mL of solution contains 1.34 mg semaglutide*. One pre-filled pen contains 4 doses of 0.5 mg. _Wegovy 1 mg FlexTouch solution for injection _ Each pre-filled pen contains 4 mg semaglutide* in 3 mL solution. One mL of solution contains 1.34 mg semaglutide*. One pre-filled pen contains 4 doses of 1 mg. _Wegovy 1.7 mg FlexTouch solution for injection _ Each pre-filled pen contains 6.8 mg semaglutide* in 3 mL solution. One mL of solution contains 2.27 mg semaglutide*. One pre-filled pen contains 4 doses of 1.7 mg. _Wegovy 2.4 mg FlexTouch solution for injection _ Each pre-filled pen contains 9.6 mg semaglutide* in 3 mL solution. One mL of solution contains 3.2 mg semaglutide*. One pre-filled pen contains 4 doses of 2.4 mg. *human glucagon-like peptide-1 (GLP-1) analogue produced in _Saccharomyces cerevisiae_ cells by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection) Clear and colourless isotonic solution; pH=7.4. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of • ≥30 kg/m 2 (obesity), or • ≥27 kg/m 2 to <30 kg/m 2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease Izlasiet visu dokumentu